Avrobio Stock News

AVROBIO (AVRO) granted non-statutory stock options for the purchase of up to 30.5K shares to three new employees as inducement awards.The stock options were granted on Jan

The stock price of Avrobio Inc (NASDAQ: AVRO) fell by 36.63% in the most recent trading session. This is why it happened.

AVROBIO Inc (NASDAQ: AVRO) dropped by 30% after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fab

Codiak BioSciences (NASDAQ:CDAK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership. Risk & Volatility Codiak BioSciences has a beta of 4.13, indicating that its share price is []

Codiak BioSciences (NASDAQ:CDAK) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Volatility and Risk Codiak BioSciences has a beta of 4.13, suggesting that its stock price is []

AVROBIO Inc. (NASDAQ:AVRO)s traded shares stood at 0.73 million during the last session, with the companys beta value hitting 1.40. At the close of trading, the stocks price was $3.73, to imply a decrease of -6.52% or -$0.26 in intraday trading. The AVRO shares 52-week high remains $20.07, putting it -438.07% down since that peak AVROBIO Inc. (NASDAQ: AVRO) Stocks Fall -73.24% YTD; What Next For It? Read More »

AvroBio Inc (AVRO) shares closed today at 1.5% above its 52 week low of $4.02, giving the company a market cap of $178M. The stock is currently down 70.7% year-to-date, down 70.9% over the past 12 months, and down 86.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 312.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 124.6% The company's stock price performance over the past 12 months lags the peer average by 178.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AvroBio Inc (AVRO) shares closed today 11.1% lower than it did at the end of yesterday. The stock is currently down 70.7% year-to-date, down 70.9% over the past 12 months, and down 86.9% over the past five years. Today, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 2.2%. Trading Activity Shares traded as high as $5.07 and as low as $4.02 this week.Shares closed 79.7% below its 52-week high and 1.5% above its 52-week low.Trading volume this week was 174.5% higher than the 10-day average and 312.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 124.6% The company's stock price performance over the past 12 months lags the peer average by 178.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), Nov. 21-23, 2021, in Sydney, Australia. Other presentations include

Wall Street analysts expect that AVROBIO, Inc. (NASDAQ:AVRO) will report earnings of ($0.76) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for AVROBIOs earnings. The lowest EPS estimate is ($0.81) and the highest is ($0.74). AVROBIO reported earnings of ($0.73) per share in the same quarter last year, which []

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc

Tuesday's futures were fairly positive after a somewhat mixed start to the week.